Nuvation Bio Inc. (NUVB) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$51.04M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $3.88M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$56.43M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$63.59M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$51.04M | (m) | $31.69M | (m) | (m) | -$42.97M* | (m) | $30.66M | $42.59M | $0.00 |
| 2026-03-31 | Reported | (m) | $3.88M | (m) | $83.23M | (m) | (m) | $5.07M | (m) | $35.05M | $38.31M | $0.00 |
| 2025-09-30 | Reported | (m) | -$56.43M | (m) | $13.12M | (m) | (m) | -$52.89M* | $3.35M | $28.85M | $37.36M | $0.00 |
| 2025-06-30 | Reported | (m) | -$63.59M | (m) | $4.83M | (m) | (m) | -$48.18M* | $2.58M | $27.36M | $38.48M | $0.00 |
| 2025-03-31 | Reported | (m) | -$59.00M | (m) | $3.08M | (m) | (m) | -$42.63M | $2.09M | $24.60M | $35.39M | $0.00 |
| 2024-09-30 | Reported | (m) | -$48.10M | (m) | $727.00K | (m) | (m) | -$31.09M* | $1.51M | $27.73M | $19.58M | $0.00 |
| 2024-06-30 | Reported | (m) | -$470.38M | (m) | $1.44M | (m) | (m) | -$37.32M* | $1.35M | $29.25M | $16.16M | $0.00 |
| 2024-03-31 | Reported | (m) | -$20.20M | (m) | $0.00 | (m) | (m) | -$15.70M | $0.00 | $12.84M | $7.36M | $0.00 |
| 2023-09-30 | Reported | (m) | -$26.34M | (m) | $0.00 | (m) | (m) | -$16.16M* | (m) | $18.56M | $7.78M | $0.00 |
| 2023-06-30 | Reported | (m) | -$26.13M | (m) | $0.00 | (m) | (m) | -$17.48M* | (m) | $18.59M | $7.54M | $0.00 |
| 2023-03-31 | Reported | (m) | -$26.52M | (m) | (m) | (m) | (m) | -$19.33M | (m) | $18.79M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$29.34M | (m) | (m) | (m) | (m) | -$28.09M* | (m) | $21.29M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$37.87M | (m) | (m) | (m) | (m) | -$26.92M* | (m) | $28.92M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$28.19M | (m) | (m) | (m) | (m) | -$24.93M | (m) | $20.73M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$22.79M | (m) | (m) | (m) | (m) | -$13.15M* | (m) | $17.12M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$20.43M | (m) | (m) | (m) | (m) | -$16.83M* | (m) | $14.03M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$20.48M | (m) | (m) | (m) | (m) | -$14.73M | (m) | $15.88M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$11.55M | (m) | (m) | (m) | (m) | -$8.04M* | (m) | $8.63M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$9.02M | (m) | (m) | (m) | (m) | -$24.27M* | (m) | $7.34M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$9.22M | (m) | (m) | (m) | (m) | $8.72M | (m) | $7.29M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$213.06M | (m) | $62.90M | (m) | (m) | -$173.43M | (m) | $115.11M | $151.56M | $0.00 |
| 2024-12-31 | Reported | (m) | -$592.63M | (m) | $7.87M | (m) | (m) | -$130.41M | $7.08M | $99.12M | $69.23M | $0.00 |
| 2023-12-31 | Reported | (m) | -$99.82M | (m) | $0.00 | (m) | (m) | -$68.00M | $0.00 | $71.29M | $28.53M | $0.00 |
| 2022-12-31 | Reported | (m) | -$119.73M | (m) | (m) | (m) | (m) | -$96.11M | (m) | $87.81M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$93.32M | (m) | (m) | (m) | (m) | -$68.19M | (m) | $69.04M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$43.55M | (m) | (m) | (m) | (m) | -$36.53M | (m) | $32.60M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |